NASDAQ:RENB

Renovaro (RENB) Stock Price, News & Analysis

$1.53
-0.17 (-10.00%)
(As of 04/26/2024 ET)
Today's Range
$1.50
$2.10
50-Day Range
$1.53
$3.23
52-Week Range
$0.39
$5.25
Volume
1.04 million shs
Average Volume
193,916 shs
Market Capitalization
$219.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RENB stock logo

About Renovaro Stock (NASDAQ:RENB)

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

RENB Stock Price History

RENB Stock News Headlines

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Renovaro Shareholder Notice
Renovaro Shareholder Alert
RENB Apr 2024 2.500 call
Renovaro Ongoing Investor Alert
Renovaro Biosciences Inc.: Statement of Renovaro Inc
Statement of Renovaro Inc
Statement of Renovaro Inc
Renovaro Investor Alert
See More Headlines
Receive RENB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
4/27/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RENB
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-39,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.80 per share

Miscellaneous

Free Float
112,463,000
Market Cap
$219.82 million
Optionable
Optionable
Beta
0.27
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Hon. Mark R. Dybul M.D. (Age 60)
    CEO, Director & Member of HBV Scientific Advisory Board
    Comp: $764.58k
  • Dr. Francois Binette M.Sc. (Age 60)
    Ph.D., COO and Executive VP for Research & Development
    Comp: $504.38k
  • Dr. Serhat Gümrükcü
    Co-Founder & Inventor
  • Mr. Simon Tarsh (Age 62)
    Interim Chief Financial Officer
  • Mr. Greg Duczynski Ph.D.
    Senior Vice President for Clinical Operations

RENB Stock Analysis - Frequently Asked Questions

How have RENB shares performed in 2024?

Renovaro's stock was trading at $3.17 on January 1st, 2024. Since then, RENB shares have decreased by 51.7% and is now trading at $1.53.
View the best growth stocks for 2024 here
.

Are investors shorting Renovaro?

Renovaro saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 90.2% from the March 15th total of 1,220,000 shares. Based on an average daily trading volume, of 295,300 shares, the days-to-cover ratio is currently 7.9 days. Approximately 2.3% of the shares of the company are sold short.
View Renovaro's Short Interest
.

When is Renovaro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our RENB earnings forecast
.

How were Renovaro's earnings last quarter?

Renovaro Inc. (NASDAQ:RENB) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.07) earnings per share for the quarter.

What ETF holds Renovaro's stock?

Amplify Treatments, Testing and Advancements ETF holds 33,976 shares of RENB stock, representing 0.81% of its portfolio.

How do I buy shares of Renovaro?

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RENB) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners